Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  aldesleukin
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-25 of 97 for your search:
Start Over
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 12PLK02, NCT01856023
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 30 and under at diagnosis
Sponsor: NCI
Protocol IDs: NCI-2009-01064, CDR0000069018, COG-ANBL0032, ANBL0032, U10CA180886, U10CA030969, U10CA098543, COG-P9842, NCT00026312
Treating Patients With Childhood Acute Myeloid Leukemia With Interleukin-2
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: Other
Protocol IDs: P030441, AOM 03142, NCT00149162
Gene Expression Profiling of Breast Cancer Cells Predict the Response of Malignant Pleural Effusion
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: GMPE, NCT01256801
High Risk Neuroblastoma Study 1.7 of SIOP-Europe (SIOPEN)
Phase: Phase III
Type: Treatment
Status: Active
Age: 1 month to 21 years
Sponsor: Other
Protocol IDs: HR-NBL-1.7 / SIOPEN, NCT01704716
Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: M14TIL, NCT02278887
Immunotherapy for Colorectal Cancers Using CEA-Pulsed Dendritic Cells and Subsequent IL-2 Treatment
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 20 to 75
Sponsor: Other
Protocol IDs: 27MD02, NCT00154713
The Role of Peptide-Loaded Dendritic Cells to Augment the Therapeutic Effect of Interleukin-2
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: pepDCIL2- HMO-CTIL, NCT00279058
Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02900, RPCI #23, CDR0000662915, NCI 7870, I 145208, 7870, P30CA016056, U01CA062505, U01CA070095, U01CA076576, UM1CA186691, UM1CA186712, NCT01038778
Peptide Vaccination Associated With Tumoral Immunomodulation in Patients With Advanced Metastatic Melanoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Luc 10-002, NCT01191034
CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 110013, 11-C-0013, NCT01218867
Dendritic Cell (DC) Activated Cytokine-induced Killer Cell (DCIK) Combined With DC Treatment for Glioma
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 to 70
Sponsor: Other
Protocol IDs: DCCIK001, NCT01235845
IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: 2011-0073, NCI-2011-02768, NCT01409174
CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 110266, 11-C-0266, NCT01454596
Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UPCI 11-080, NCT01550367
CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 66
Sponsor: NCI
Protocol IDs: 120111, 12-C-0111, NCT01583686
Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: 2498.00, NCI-2011-03362, P01CA018029, P30CA015704, NCT01640301
Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 21
Sponsor: Other
Protocol IDs: 012010, 2009-018077-31, NCT01701479
Cord Blood Natural Killer Cells for Myeloma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 2011-0379, NCI-2014-01096, NCT01729091
T-Cells Transduced With Either CXCR2 or Nerve Growth Factor Receptor (NGFR)
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 14 and over
Sponsor: NCI, Other
Protocol IDs: 2009-0471, 2RO1CA116206-06, NCI-2014-02655, NCT01740557
Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 2586.00, NCI-2012-02779, 2586, P30CA015704, NCT01758458
Natural Killer (NK) Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 65 and under
Sponsor: Other
Protocol IDs: 2012-0819, RP110553-P3), NCI-2013-00993, NCT01823198
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 66
Sponsor: NCI
Protocol IDs: 140052, 14-C-0052, NCT02111850
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 66
Sponsor: NCI
Protocol IDs: 140110, 14-C-0110, NCT02153905
Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 13 moths to 29 years
Sponsor: NCI, Other
Protocol IDs: 2013-171, NCI-2014-01149, P30CA022453, NCT02173093
Start Over